Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TNK2 | Q07912 | 1/20 | 0.68 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.57 |
| ▸ | HPGD | P15428 | 2/20 | 0.57 |
| ▸ | TSHR | P16473 | 1/20 | 0.57 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.57 |
| ▸ | AURKA | O14965 | 11/20 | 0.56 |
| ▸ | CHEK1 | O14757 | 3/20 | 0.56 |
| ▸ | MAP2K1 | Q02750 | 1/20 | 0.56 |
| ▸ | EGFR | P00533 | 2/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.54 |
| ▸ | UBE2N | P61088 | 1/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.52 |
| ▸ | MEN1 | O00255 | 1/20 | 0.52 |
| ▸ | RAD52 | P43351 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13271835 | 0.81 | TNK2 (0.68) | TNK2ALDH1A1HPGDTSHRHSD17B10 | |
| SCHEMBL735560 | 0.81 | TNK2 (0.68) | TNK2ALDH1A1HPGDTSHRHSD17B10 | |
| SCHEMBL2965887 | 0.81 | TNK2 (1.00) | TNK2ALDH1A1HPGDTSHRHSD17B10 | |
| SCHEMBL2976986 | 0.81 | TNK2 (0.68) | TNK2ALDH1A1HPGDTSHRHSD17B10 | |
| SCHEMBL1787179 | 0.80 | TNK2 (0.58) | TNK2ALDH1A1HPGDTSHRHSD17B10 | |
| SCHEMBL2966671 | 0.77 | ALDH1A1 (0.64) | TNK2ALDH1A1HPGDTSHRHSD17B10 | |
| SCHEMBL3561541 | 0.74 | TNK2 (0.51) | TNK2ALDH1A1HPGDTSHRHSD17B10 | |
| SCHEMBL13632594 | 0.74 | AURKA (0.81) | TNK2ALDH1A1HPGDTSHRHSD17B10 | |
| SCHEMBL2977130 | 0.74 | TNK2 (0.58) | TNK2ALDH1A1HPGDTSHRHSD17B10 | |
| SCHEMBL6848486 | 0.74 | TNK2 (0.58) | TNK2ALDH1A1HPGDTSHRHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7776867-B2 | Furanopyrimidines | AMGEN INC. (US) | 2010-08-17 | — | — | US | disclosed |
| US-7776867-B2 | Furanopyrimidines | AMGEN INC. (US) | 2010-08-17 | — | — | US | disclosed |
| US-7776867-B2 | Furanopyrimidines | AMGEN INC. (US) | 2010-08-17 | — | — | US | disclosed |
| EP-1768986-A2 | FURANOPYRIMIDINES | Amgen Inc. (US) | 2007-04-04 | — | — | EP | disclosed |
| US-20060040961-A1 | Furanopyrimidines | AMGEN INC. | 2006-02-23 | — | — | US | disclosed |
| WO-2006004658-A2 | FURANOPYRIMIDINES | AMGEN INC. (US) | 2006-01-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060040961-A1 | Furanopyrimidines | TYMS, IDO1, NFATC1 | TNK2 1075/4885ALDH1A1 159/4885HPGD 1536/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.